MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short-and long-term immune assays

Gene Therapy

Volumn 17, Issue 11, 2010, Pages 1372-1383

  Kutscher, S ^a   Allgayer, S ^a,b   Dembek, C J ^a   Bogner, J R ^c   Protzer, U ^a,b   Goebel, F D ^c   Erfle, V ^a,b   Cosma, A ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

HIV 1; MVA; proliferation; T cell response; therapeutic vaccination

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; GAMMA INTERFERON; INTERLEUKIN 2; NEF PROTEIN; VIRUS VECTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE;

AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOASSAY; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA; VACCINIA VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1; POXVIRIDAE; VACCINIA VIRUS ANKARA;

EID: 78149466327     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.90     Document Type: Article

References (55)

1. Noe A, Plum J, Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 2005; 55: 410-412.
2. Gudmundsdotter L, Sjodin A, Bostrom AC, Hejdeman B, Theve-Palm R, Alaeus A et al. Therapeutic immunization for HIV. Springer Semin Immunopathol 2006; 28: 221-230.
3. Dorrell L. Therapeutic immunization strategies for the control of HIV-1. Expert Rev Vaccines 2005; 4: 513-520.
4. Cosma A, Nagaraj R, Buhler S, Hinkula J, Busch DH, Sutter G et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003; 22: 21-29.
5. Makedonas G, Betts MR. Polyfunctional analysis of human Tcell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol 2006; 28: 209-219.
6. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247-258.
7. Elias D, Akuffo H, Britton S. PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 2005; 99: 363-368.
8. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 4781-4789.
9. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79: 14169-14178.
10. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004; 103: 966-972.
11. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4T cell responses is associated with nonprogres-sion in HIV-1 infection. J Immunol 2002; 169: 6376-6385.
12. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, Robinson HL et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4T cells coexpressing three cytokines. J Virol 2007; 81: 12071-12076.
13. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007; 37: 3089-3100.
14. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843-850.
15. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007; 204: 1405-1416.
16. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3: 1061-1068.
17. Jagannathan P, Osborne CM, Royce C, Manion MM, Tilton JC, Li L et al. Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytome-galovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. J Virol 2009; 83: 2728-2742.
18. Kutscher S, Dembek CJ, Allgayer S, Heltai S, Stadlbauer B, Biswas P et al. The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT. AIDS Res Ther 2008; 5: 22.
19. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006; 6: 417-423.
20. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004; 200: 701-712.
21. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 2006; 211: 81-92.
22. MacLeod MK, McKee A, Crawford F, White J, Kappler J, Marrack P. CD4 memory T cells divide poorly in response to antigen because of their cytokine profile. Proc Natl Acad Sci USA 2008; 105: 14521-14526.
23. Nomura LE, Emu B, Hoh R, Haaland P, Deeks SG, Martin JN et al. IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells. AIDS Res Ther 2006; 3: 18.
24. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
25. Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
26. Kornbluth RS. The emerging role of CD40 ligand in HIV infection. J Leukoc Biol 2000; 68: 373-382.
27. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M et al. Direct access to CD4+ Tcells specific for defined antigens according to CD154 expression. Nat Med 2005; 11: 1118-1124.
28. Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PTet al. Functional skewing of the global CD8Tcell population in chronic hepatitis B virus infection. J Exp Med 2008; 205: 2111-2124.
29. Iyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, Sekaly RP et al. Diminished proliferation of human immuno¬deficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol 2003; 77: 10900-10909.
30. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4T cells are functionally superior to single-cytokine-producing cells. J Virol 2007; 81: 8468-8476.
31. Robbins GK, Addo MM, Troung H, Rathod A, Habeeb K, Davis B et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immuniza¬tion. Aids 2003; 17: 1121-1126.
32. Levy Y, Gahery-Segard H, Durier C, Lascaux AS, Goujard C, Meiffredy V et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. Aids 2005; 19: 279-286.
33. Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, Suttill A et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 2006; 80: 4705-4716.
34. Moss RB, Webb E, Giermakowska WK, Jensen FC, Savary JR, Wallace MR et al. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant. J Acquir Immune Defic Syndr 2000; 24: 264-269.
35. Valor L, Navarro J, Carbone J, Rodriguez-Sainz C, Gil J, Lopez F et al. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy. Vaccine 2008; 26: 2738-2745.
36. Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 2008; 26: 6883-6893.
37. Harrer E, Bauerle M, Ferstl B, Chaplin P, Petzold B, Mateo L et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immuno-genicity and influence on viral load during treatment interrup¬tion. Antivir Ther 2005; 10: 285-300.
38. Ondondo BO, Yang H, Dong T, di Gleria K, Suttill A, Conlon C et al. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimu¬lates broad functional CD4+ Tcell responses. Eur J Immunol 2006; 36: 2585-2594.
39. Pancre V, Delhem N, Yazdanpanah Y, Delanoye A, Delacre M, Depil S et al. Presence of HIV-1 Nef specific CD4Tcell response is associated with non-progression in HIV-1 infection. Vaccine 2007; 25: 5927-5937.
40. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15: 293-299.
41. Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, Schatzl H et al. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. Aids Res Hum Retroviruses 2007; 23: 782-793.
42. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 2006; 211: 236-254.
43. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003; 198: 1909-1922.
44. Day CL, Kiepiela P, Leslie AJ, van der Stok M, Nair K, Ismail N et al. Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol 2007; 81: 434-438.
45. Subauste CS, Subauste A, Wessendarp M. Role of CD40-dependent down-regulation of CD154 in impaired induction of CD154 in CD4(+) Tcells from HIV-1-infected patients. J Immunol 2007; 178: 1645-1653.
46. Cox KS, Clair JH, Prokop MT, Sykes KJ, Dubey SA, Shiver JW et al. DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J Virol 2008; 82: 8161-8171.
47. Steinbrook R. One step forward, two steps back\will there ever be an AIDS vaccine? N Engl J Med 2007; 357: 2653-2655.
48. Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, Baak I et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immuno¬deficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 2008; 82: 2975-2988.
49. Obst R, van Santen HM, Mathis D, Benoist C. Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. J Exp Med 2005; 201: 1555-1565.
50. Winstone N, Guimaraes-Walker A, Roberts J, Brown D, Loach V, Goonetilleke N et al. Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay. Eur J Immunol 2009; 39: 975-985.
51. Guimaraes-Walker A, Mackie N, McCormack S, Hanke T, Schmidt C, Gilmour J et al. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008; 26: 6671-6677.
52. Hanke T, Goonetilleke N, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA-and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 2007; 88 (Part 1): 1-12.
53. Slifka MK. The future of smallpox vaccination: is MVA the key? Med Immunol 2005; 4: 2.
54. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998; 79 (Part 2): 347-352.
55. Vardas E, Butto S, Glashoff R, Malnati MS, Poli G, Clerici M. Preparing for phase II/III HIV vaccine trials in Africa. Microbes Infect 2005; 7: 1436-1444.